#USA #Boston #oncology #TransCode Therapeutics #RNA-based therapies

TransCode Therapeutics Announces Leadership Transition

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a pioneering clinical-stage company focused on immuno-oncology and RNA-based treatments, has recently announced an important change in its leadership.

On September 10, 2026, the company revealed the retirement of its Chief Financial Officer (CFO) Tom Fitzgerald, who has been at the helm since July 2018. Under Fitzgerald’s financial guidance, TransCode advanced through pivotal milestones, including its initial public offering and the launch of its lead therapeutic candidate, TTX-MC138. Indeed, Fitzgerald's efforts have been instrumental in steering the company towards acquiring Polynoma and securing a licensing deal with Oncolytics, thereby expanding its innovative oncology product pipeline.

In a statement, Philippe P. Calais, Ph.D., Chairman of the Board and CEO, expressed gratitude for Fitzgerald's years of dedication. He highlighted Fitzgerald's unwavering commitment, stating, "From our beginnings as a small discovery-focused entity with ambitious goals, Tom has tirelessly worked to secure our funds and ensure our trajectory towards providing impactful therapies for cancer patients. We wish him a happy retirement, well deserved after years of service."

Effective immediately, in light of Fitzgerald's resignation from both his CFO role and the company's board of directors, John Tattory has been appointed as the Interim CFO. Tattory brings over 25 years of robust experience in financial management, with an extensive history leading both U.S. and international financial operations within the pharmaceutical and biotech sectors. His career includes roles as Finance Director at notable organizations like Bristol-Myers Squibb and Tyco International, along with serving as CFO for Cerapedics, Inc. and Windtree Therapeutics, Inc. Currently, he manages consulting CFO services at Stout Risius Ross, LLC, specializing in private life science firms. His wide-ranging expertise spans areas including capital raising and investor relations, financial planning, analysis, and public financial reporting.

About TransCode Therapeutics
TransCode Therapeutics aims to transform cancer treatment through its focus on advanced therapies. The company’s flagship product, TTX-MC138, targets metastatic tumors that display high levels of microRNA-10b, recognized as a reliable marker for metastasis. Additionally, TransCode boasts a suite of first-of-their-kind therapeutic candidates designed to empower the immune system to seek out and eliminate cancer cells effectively.

Looking Forward
In light of these leadership changes and driven by its innovative pipeline, TransCode Therapeutics is positioning itself to enhance its potential in the oncology landscape further. The company's commitment to bringing groundbreaking treatments to the market remains solid, supported by a strong leadership team as it navigates the complexities of drug development and commercialization.

Note on Forward-Looking Statements
This release includes various forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future activities and are subject to risks and uncertainties that could lead to materially different results. Risks involve drug discovery challenges, clinical trial consistency, financial viability, regulatory timelines, and competitive pressures, among others. For a detailed discussion on these factors, please refer to the 'Risk Factors' section in TransCode's Annual Report on Form 10-K for the fiscal year ending December 31, 2025.

TransCode Therapeutics is committed to transparency and continual progress toward enriching patient lives through innovative cancer therapies.